Express News | CorMedix Inc. Announces Outpatient Availability of Defencath

ReutersJul 3 08:03 ET

CorMedix Inc. Announces Outpatient Availability of DefenCath

BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today

GlobeNewswireJul 3 08:00 ET

CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH

July 3, 2024Berkeley Heights, NJ – July 3, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, tod

CorMedixJul 3 00:00 ET

Truist Financial Initiates CorMedix(CRMD.US) With Buy Rating

Truist Financial analyst Nicole Germino initiates coverage on $CorMedix(CRMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 57.7% and a total average return of 67

moomoo NewsJun 20 07:32 ET · Ratings

Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $10

Needham analyst Serge Belanger maintains $CorMedix(CRMD.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 41.9% and a total av

moomoo NewsJun 18 14:32 ET · Ratings

CorMedix to Start DefenCath Label Expansion Program This Year

Seeking AlphaJun 18 08:57 ET